4.7 Article

The Use of Aromatase Inhibitors for Ovulation Induction and Superovulation

Journal

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 98, Issue 5, Pages 1838-1844

Publisher

ENDOCRINE SOC
DOI: 10.1210/jc.2013-1328

Keywords

-

Funding

  1. National Institutes of Health (NIH) [K12HD050121, R37HD038691]
  2. American Society for Reproductive Medicine career development award

Ask authors/readers for more resources

Context: Anovulation is likely responsible for 20% of female infertility. Although clomiphene citrate remains the first-line therapy for ovulation induction in anovulatory patients who are not estrogen-deficient and to treat unexplained infertility, there remains a discrepancy between ovulation and conception rates with its use, attributed to its antiestrogenic effects on cervical mucus and the endometrium. Alternative agents, including aromatase inhibitors, have been used that have not been associated with these side effects. Evidence Acquisition: A literature search was conducted to specifically explore the use of aromatase inhibitors for ovulation induction and superovulation. Evidence Synthesis: Recent studies have found that aromatase inhibitors may be safe and useful agents for ovulation induction in patients with polycystic ovarian syndrome as well a treatment option for superovulation in patients with either unexplained infertility or endometriosis. Conclusions: Aromatase inhibitors may be an effective alternative treatment to clomiphene citrate for both ovulation induction and superovulation. (J Clin Endocrinol Metab 98: 1838-1844, 2013)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available